Literature DB >> 15269884

The role of stem cell transplantation in chronic lymphocytic leukemia.

V Rizouli1, J g Gribben Jg.   

Abstract

Chronic lymphocytic leukemia (CLL) generally follows an indolent clinical course and usually occurs in the elderly. However, the disease is heterogeneous with some patients having a more aggressive clinical course and short survival. Although the role of fludarabine in combination with other chemotherapy drugs and/or monoclonal antibody therapy appears promising, to date chemotherapy has not been curative in this disease. At present, the only potential cure for CLL appears to be stem cell transplantation (SCT), but its role in the management of CLL has not been established. In particular, patient selection for consideration of SCT, timing of SCT in the clinical course of CLL, selection of autologous versus allogeneic SCT, use of nonmyeloablative regimens, and exploitation of the graft-versus-leukemia (GVL) effect are currently under investigation.

Entities:  

Mesh:

Year:  2004        PMID: 15269884     DOI: 10.1053/j.seminhematol.2004.05.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  4 in total

Review 1.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  New agents in chronic lymphocytic leukemia.

Authors:  Tadeusz Robak
Journal:  Curr Treat Options Oncol       Date:  2006-05

3.  Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.

Authors:  Sona Peková; Jana Marková; Petr Pajer; Michal Dvorák; Petr Cetkovský; Jirí Schwarz
Journal:  Mol Diagn       Date:  2005

4.  High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.

Authors:  Ignazio Majolino; Marco Ladetto; Anna Locasciulli; Daniela Drandi; Fabio Benedetti; Andrea Gallamini; Teodoro Chisesi; Angelo De Blasio; Mario Boccadoro; Corrado Tarella
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.